Navamedic ASA (OB:NAVA) made an offer to acquire Sensidose AB (NGM:SENSI) for SEK 96 million on March 29, 2023. As of April 24, 2023, Navamedic ASA has amended its Offer to SEK 8.00 per share in Sensidose AB. As of May 10, 2023, Navamedic increased offer price to SEK 8.50 cash per share in Sensidose.

The Offer is conditional upon certain customary conditions on the Swedish market, including but not limited to Navamedic becoming the owner of shares in Sensidose representing more than 90 percent of the total number of shares and votes in Sensidose (on a fully diluted basis). The consideration payable in respect of the Offer is financed in full by a combination of funds available to Navamedic and debt financing provided on terms which are customary for financing of public offers on the Swedish market. Upon acceptance of 90% stake in Sensidose, Navamedic intends to commence compulsory redemption proceedings to acquire all remaining shares.

The offer is subject to minimum tender and has been accepted by the Board of Sensidose unanimously. As of April 25, 2023, Navamedic has resolved to extend the acceptance period up to and including May 15, 2023. As of May 10, 2023, the acceptance period for the offer has been extended up to and including May 25, 2023.Carnegie Investment Bank is acting as financial advisor to Navamedic.

Roschier Advokatbyrå AB and Advokatfirmaet Thommessen AS are acting as legal advisors to Navamedic. First House AS is acting as communications and IR advisor to Navamedic. Fredersen Advokatbyrå AB is acting as legal advisor to Sensidose.

The recommendation is supported by a fairness opinion provided by Eminova Partners Corporate Finance AB.